Want to join the conversation?
$BAX paid approx. $14MM to acquire the rights to cefazolin injection in GALAXY Container (2 g/100 mL) in 3Q15. The purchase price was capitalized as an intangible asset and $BAX is amortizing the asset over the estimated economic life. In the Other franchise, sales fell mainly due to one of $BAX's pharma partners assuming their own production.
Unicorn Frappuccino. The latest hit from $SBUX. Can't wait to see how this will affect its results.
At what point should $AMZN consider a stock split? $1000 per share seems pretty high.